Diffusion Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 29 2018 - 8:00AM
Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN)
(“Diffusion” or “the Company”), a clinical-stage biotechnology
company focused on improving patient outcomes in unmet medical
needs using its novel small molecule trans sodium crocetinate
(TSC), today announced that management will present an overview of
the Company and recent advancements of its lead product candidate,
trans sodium crocetinate (TSC), at the 20th Annual Rodman &
Renshaw Global Investment Conference, sponsored by H.C. Wainwright
& Co., on Thursday, September 6, 2018 at 1:45 p.m. Eastern
time. The conference will be held on September 4-6, 2018 at the St.
Regis New York Hotel in New York City.
To listen to the presentation live, investors
may visit the Investor Relations section of Diffusion
Pharmaceuticals’ website at www.diffusionpharma.com. An archived
webcast of the presentation will also be available on the Company’s
website for a period of time.
About Diffusion Pharmaceuticals
Inc.
Diffusion Pharmaceuticals Inc. is a
clinical-stage biotechnology company focused on improving patient
outcomes in unmet medical needs using its novel small molecule
trans sodium crocetinate (TSC). Diffusion is developing TSC for use
in conditions where hypoxia (oxygen deprivation) is known to
diminish the effectiveness of standard of care (SOC) treatments. In
oncology, TSC targets the cancer's hypoxic micro-environment,
re-oxygenating treatment-resistant tissue and making the cancer
cells more vulnerable to the therapeutic effects of SOC treatments
without the apparent occurrence of any serious side effects. In
non-oncology indications, therapeutic benefit would be achieved
directly through re-oxygenation of tissue threatened with cell
death from hypoxia.
The INvestigation of TSC Against Cancerous
Tumors (INTACT) Phase 3 randomized, controlled registration trial
with TSC and SOC chemotherapy and radiation, compared with SOC
alone in 236 patients who have been newly diagnosed with inoperable
glioblastoma multiforme (GBM) brain cancer, is underway. In this
study, TSC with concomitant temozolomide is being assigned to the
first 8 subjects enrolled, and these patients will undergo
radiation therapy plus temozolomide and TSC treatment through the
normal six-week RT treatment period. During the subsequent
temozolomide treatment period these subjects will be assigned TSC
at ascending doses and studied in parallel for 2 full 28-day
cycles. The Data Safety Monitoring Board will examine the resultant
data and based on their observations may recommend the continued
use of the starting TSC dose or another dose for those patients
remaining to be randomized into the study.
A Phase 2 TSC clinical trial was completed in
the second quarter of 2015 and evaluated 59 patients with newly
diagnosed GBM. This open-label, historically controlled study
demonstrated a favorable safety and efficacy profile for TSC
combined with SOC, including a 37% improvement in overall survival
compared with the control group at two years. A particularly
strong efficacy signal was seen in the subset of inoperable
patients where survival of TSC-treated patients at two years was
nearly four-fold higher compared with the controls.
Due to its novel mechanism of action, TSC has
safely re-oxygenated a range of tumor types in preclinical and
clinical studies. Diffusion believes the therapeutic
potential of TSC is not limited to specific tumors, thereby making
it potentially useful to improve SOC treatments of other
life-threatening cancers. Additional studies under
consideration include Phase 2 trials in pancreatic cancer and brain
metastases, with study initiation subject to receipt of additional
funding or collaborative partnering. The Company also believes that
TSC has potential application in other indications involving
hypoxia including stroke, where the Company recently announced its
Pre-Hospital Ambulance Stroke Trial - TSC (PHAST-T) study to be
conducted in co-operation with the University of California Los
Angeles (UCLA) and the University of Virginia (UVA) to test TSC in
stroke patients in an in-ambulance clinical trial setting.
Contacts:David Kalergis,
CEODiffusion Pharmaceuticals Inc.(434)
220-0718dkalergis@diffusionpharma.comorLHA Investor RelationsKim
Sutton Golodetz(212) 838-3777kgolodetz@lhai.com
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Apr 2023 to Apr 2024